ICT Compliance is a tech company specializing in authentication solutions.
Willog specializes in providing a customizable data logging and management system that enables comprehensive monitoring of logistics from production to consumer delivery. The company focuses on capturing critical environmental parameters, such as temperature, humidity, shock, and light, during transit. By offering cloud-based software as a service (SaaS), Willog facilitates analysis and oversight of the logistics process, allowing businesses to identify issues and improve communication regarding transportation progress. This approach transforms traditional opaque logistics systems into transparent ones, enhancing the efficiency and reliability of supply chain operations.
Happy Moonday Inc. is a South Korean company established in 2017 that specializes in the manufacture and sale of organic sanitary products. The company offers a range of female healthcare items, including organic cotton sanitary napkins, tampons, menstrual cups, and underwear, as well as feminine wash and heating patches. Additionally, Happy Moonday provides menstrual cycle tracking applications to assist women in managing their health and alleviating discomfort during their menstrual cycles. By focusing on organic materials, the company aims to promote healthier choices for women.
A mathematical problem solving application for middle and high school students.
Developer of an international gifting service platform intended to make gifting easy for people. The company's platform allows the purchase and presentation of gift cards from popular brands in the US, South Korea and Canada, through easy card payment and real-time transmission, enabling users to send easy to send gifts to family back home from abroad.
S-Alpha Therapeutics Inc. is a digital therapeutics company based in Seoul, South Korea, founded in 2019. The company focuses on researching and developing health applications and platform technologies aimed at treating a variety of diseases. Its product lineup includes SAT-001, an application for eye disease; SAT-002, designed for neurological conditions; SAT-003, which aids in cancer recovery and treatment; and SAT-008, a public crisis application addressing social issues. In addition to these applications, S-Alpha Therapeutics also develops therapeutic devices that support its digital health solutions. The company aims to provide innovative treatment methods for areas such as ophthalmology, neuropsychiatry, cancer, and immunology, addressing unmet medical needs through digital approaches.
Wavebridge is developing solutions with the goal of providing an integrated AI platform for domestic financial institutions. Services provided include financial data analysis module, financial product valuation module, risk analysis module and AI transaction solutions. Wavebridge is creating an excellent institutional network based on core competencies such as an experienced workforce suitable for building digital finance and certified technological strength by providing global solutions. Vision: “AI Automatic Trading, Integrated Asset Management Platform"
Reebonz Korea., Ltd engages in the import, export, wholesale, and retail of luxury products for men and women. The company offers bags/handbags, wallets, watch/accessories, shoes, clothing, cosmetics, and fashion accessories. It also offers products online. The company is based in Seoul, South Korea.
PeopleBio, Inc. is a biotechnology company based in Seongnam, South Korea, established in 2002. The company focuses on developing diagnostic products for neurodegenerative diseases characterized by protein misfolding, such as Alzheimer's disease, Parkinson's disease, and Creutzfeldt-Jakob's disease. Utilizing its proprietary Multimer Detection System technology, PeopleBio employs capturing antibodies and epitope-overlapping detection antibodies to identify oligomers or multimers derived from monomers in these conditions. The company has formed strategic collaborations with several institutions, including Seoul National University Bundang Hospital and various diagnostic and research organizations, to enhance its diagnostic capabilities and expand its reach in the field of protein misfolding diseases.
GI Innovation is a South Korean bio-venture company dedicated to the research and development of innovative biologics, primarily focusing on immuno-oncology and inflammation/immunology diseases. The company leverages its GI-SMART platform technology to enhance the development process of multi-targeting fusion protein therapeutics, aiming for high quality and productivity. By integrating basic science with translational innovation, GI Innovation strives to create new therapeutic options for patients globally, particularly in the areas of immuno-oncology and allergy-related conditions.
Gencurix Inc. is a South Korean company specializing in the development of molecular diagnostic products. Founded in 2011 and headquartered in Seoul, Gencurix focuses on creating diagnostic kits aimed at improving cancer prognosis and treatment. Its product lineup includes the GenesWell BCT, a diagnostic kit for breast cancer, and the GenesWell ddEGFR Mutation Test, which is designed for detecting mutations in non-small cell lung cancer. Additionally, Gencurix offers the GenesWell CDx EGFR Mutation Test, which serves as a companion diagnostic tool for lung cancer. The company's innovative approach aims to enhance the accuracy of cancer diagnosis and treatment options available to healthcare providers.
Developer of smart sensing systems designed to monitor and manage overall safety issues including worker safety and environmental hazard detection. The company's systems are used for employee safety, asset tracking and monitoring, security control, flow management, and process efficiency, enabling clients to monitor employees' security, safety, and productivity.
Biobab AiBIO is a biotechnology company that develops drugs utilize artificial intelligence.
S-Alpha Therapeutics Inc. is a digital therapeutics company based in Seoul, South Korea, founded in 2019. The company focuses on researching and developing health applications and platform technologies aimed at treating a variety of diseases. Its product lineup includes SAT-001, an application for eye disease; SAT-002, designed for neurological conditions; SAT-003, which aids in cancer recovery and treatment; and SAT-008, a public crisis application addressing social issues. In addition to these applications, S-Alpha Therapeutics also develops therapeutic devices that support its digital health solutions. The company aims to provide innovative treatment methods for areas such as ophthalmology, neuropsychiatry, cancer, and immunology, addressing unmet medical needs through digital approaches.
OliX Pharmaceuticals is a clinical stage biotechnology company based in Suwon, South Korea, specializing in the development of RNA interference (RNAi) therapeutics aimed at treating various dermal, ophthalmic, and pulmonary diseases. The company's diverse product pipeline includes treatments such as OLX101 for skin scars, OLX102 for skin whitening, OLX103 for atopic dermatitis, OLX104 for hair loss, OLX105 for anti-wrinkle applications, and OLX106 for diabetic foot ulcers. Additionally, it is developing therapies for age-related macular degeneration, retinitis pigmentosa, lung fibrosis, asthma, influenza, neuropathic pain, liver fibrosis, and cancer immunotherapy. OliX Pharmaceuticals has also formed a collaboration with Théa to advance SiRNA therapeutics specifically for ophthalmic conditions. Established in 2010, the company leverages its proprietary RNAi technology to regulate the expression of genes associated with diseases.
Trenbe Inc. is an online fashion platform based in Seoul, South Korea, specializing in the sale of apparel, bags, shoes, and accessories for both men and women. Incorporated in 2016, the company focuses on providing luxury clothing and accessories through its online shopping mall, which features a wide range of products from various brands. Utilizing in-house technology, Trenbe aims to offer luxury goods at more affordable prices, making high-end fashion accessible to a broader audience.
5minlab (5민랩) develops mobile and Flash games. Its products include Project Jump Goox, which is a fairy-tale based game. 5minlab was established on Septemeber 23, 2013. It is based in Seoul, Korea.
Laundrygo is an on-demand laundry service that offers subscription-based cleaning solutions. The company focuses on delivering a convenient alternative to traditional laundry services by ensuring the pickup and return of customers' laundry within one day. By providing this quick turnaround at a lower cost compared to conventional laundry shops, Laundrygo aims to offer a hassle-free and efficient experience for its users.
Kukka, Inc. is a flower delivery service based in Seoul, South Korea, established in 2014. The company aims to promote the Finnish culture of enjoying flowers in everyday life within Korea. Kukka offers a variety of services, including flower subscriptions, bouquet deliveries, same-day delivery, and custom flower designs tailored for both individual and corporate clients. Its product range encompasses corporate event support flowers, promotional flower boxes, customer care flowers, and floral decorations. Additionally, Kukka provides flower art classes and accessories, making it easier for customers to incorporate fresh flowers into their spaces and events.
Provider of ride-hailing service platform intended to come up with scheduled car reservation service. The company's platform provides reservations of cars through calling as well as a selection of a variety of vehicles with simplified payment and discounts through its mobile application, enabling customers to enjoy a reservation-based travel experience.
Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.
Sparkplus is a coworking space operator based in Seoul, South Korea, founded in 2016. The company specializes in designing and managing real estate contracts, as well as overseeing interior design, construction, and furniture arrangements for office environments. By providing flexible workspace solutions, Sparkplus caters to the needs of modern businesses seeking adaptable office settings.
FamePick Inc. is a subscription-based internet platform founded in 2016 and located in Sunnyvale, California. It serves the advertising and marketing industry by providing a data-driven endorsement platform that enables marketers to find, secure, and launch celebrity-driven marketing campaigns on social media. The platform aims to create authentic celebrity experiences, allowing brands to enhance their marketing efforts through the influence of well-known personalities.
Raonsecure Co., Ltd. is an ICT security software company based in Seoul, South Korea, specializing in security solutions for financial institutions, government entities, and enterprises. Founded in 1998 and originally named Lumensoft Ltd., the company changed its name in 2012. Raonsecure primarily offers TouchEn OnePass, a biometric authentication solution designed for various applications, including payments, mobile banking, and fintech services. The company is also engaged in ICT security consulting and holds multiple patents in integrated security technologies, focusing on human/device authentication and FIDO (Fast IDentity Online) protocols based on Public Key Infrastructure (PKI) technology. Through its innovative products and services, Raonsecure aims to enhance security measures in the digital landscape.
Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.
TiBit Communications specializes in innovative technology aimed at transforming broadband access deployment in the global Service Provider markets, including cable, telecommunications, and wireless sectors. The company designs small, low-power, and cost-effective devices that can be easily integrated into existing networks. These devices facilitate multi-Gigabit connectivity and enable high-performance Ethernet switching systems to replace traditional access equipment. By virtualizing the access network, TiBit Communications helps businesses reduce operational costs and simplify their network architecture, making it easier for service providers to adapt to evolving demands.
Innopharmascreen
Series A in 2019
Innopharmascreen is a ICT based drug discovery company.
WooGene B&G Co., Ltd. is a South Korean company that develops, manufactures, and markets products for the animal health and livestock industry both domestically and internationally. Established in 1977 and headquartered in Seoul, the company offers a diverse range of products, including veterinary medicines and vaccines for various animals such as poultry, swine, bovine, equine, canine, and aquaculture species. In addition to these offerings, WooGene B&G plans to expand its operations to include the production of raw materials for human medicines, microbial pesticides, and functional health foods. The company, which was formerly known as WooJin Co., Ltd., changed its name in March 2001 to reflect its evolving business focus.
bHaptics is a developing a full-body and fully programmable haptic solution for Virtual Reality (VR)
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
Vendys Inc. is a South Korean company that provides a mobile meal voucher service aimed at enhancing employee welfare. Established in 2014, Vendys offers a digital platform that enables companies to manage dining for their employees through mobile applications. The service includes mobile food stamps, canteen meal coupons, and discount promotions, aimed at improving staff engagement and dining experiences. By partnering with local restaurants, Vendys facilitates convenient meal options for office workers, promoting a better dining culture within the workplace. The company is headquartered in Seoul and operates primarily in the staff welfare sector.
Newploy is a South Korean company founded in 2014 that specializes in workforce management software. The platform is designed to streamline various aspects of employee management, including tracking work hours, attendance, and leave, as well as calculating salaries and managing payroll. By automating these processes, Newploy enables businesses to effectively centralize and manage their staffing needs, enhancing efficiency in human resource operations.
Albam : A mobile based HR Solution that is available for both Managers(Admins) and Staffs in App both IOS & Android. The average HR manager spends 45 minutes a day to calculate time attendance & payroll. With Albam, time is reduced by 70% to only 15 minutes. Albam help enterprises in simplifying and automating their time attendance system to payroll solution. Our easy to use and simple Cloud based Human Resource solution helps companies in reducing the high costs that are often associated in the investment of Time Attendance system which includes the purchase of expensive fingerprint machines and training of IT Personnels. With Albam, employees can clock in and clock out directly right away from their smartphone, clock in and clock out has never been this easier with Albam.
Triple Corp. operates a cloud based travel platform. Its product triple, is an application which is designed to help the user in real time location sharing. The company was founded in 2016 and is based in Seongnam, South Korea.
WATCHA - Launched in AUG 2012, it quickly became Korea’s favorite movie review app - Its core competency lies in personalized recommendation technology - once users rate movie, WATCHA predicts how they will like movies they haven’t yet seen - Now provides the widest and most accurate movie, TV show and book reviews - Launched in Japan in 2015 WATCHA PLAY - Launched in JAN 2016 - Subscription VOD service for movie and TV series available on multiple devices including Web, iOS/Android mobile and tablet, Samsung/LG Smart TV, Google Chromecast, Android TV - Provides extremely accurate personalized content recommendation, powered by WATCHA - 75% of content consumed based on recommendations Comment by Apple, App Store Editor Team “Thanks to its large volume of reliable review data collected from users, WATCHA PLAY can recommend contents that perfectly satisfy my taste. Please don’t waste your time in choosing what to watch. Trust WATCHA PLAY and Enjoy tonight”
Zoyi Corporation is a retail technology company based in Seoul, South Korea, specializing in customer analytics tools for retailers. The company offers Walk Insights, an offline retail analytics solution that captures and analyzes wireless signals from mobile devices to gather real-time visitor data. This solution enables retailers to understand external traffic patterns, store visits, dwell time, and the behavior of returning customers. By leveraging advanced technology, Zoyi aims to enhance the offline shopping experience and provide valuable insights to retailers.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.
Developer of antibody immunity diagnostic kits designed for clinical, food, and life sciences testing. The company specializes in the development and production of rapid and cost-effective immunoassays for clinical, agricultural, and biological testing, enabling doctors to easily diagnose various diseases with high sensitivity.
Private Equity Round in 2017
Yanolja is the fastest-growing No.1 OTA, and the only ‘Unicorn’ among travel related companies in South Korea. In the online business, as a ‘Super App’, Yanolja provides all services for travel including accommodation, leisure and transportation. In the offline sector, it is one of the largest franchise operators in Southeast Asia, managing more than 10,000 rooms. It is also Asia’s best full-stack hospitality company, supplying an integrated hotel platform by effectively utilizing IoT, AI and blockchain technologies. Yanolja is now also one of the global Top 2 PMS providers. It has integrated entire hotel operations, covering from front office to back office including housekeeping and maintenance. Yanolja connects the B2B2C value chain of the travel industry with a one-stop network and integrates it into a single platform.
Blind is a community app that connects verified professionals to facilitate discussions on important workplace topics. Founded in 2013 and based in Irvine, California, with additional offices in Seoul and San Francisco, Blind allows users to communicate anonymously in private company channels and engage openly across various industries. With a global user base of over 4.1 million professionals, the platform serves as a space for sharing advice, providing feedback, and exploring relevant career information. By promoting transparency and fostering honest dialogue, Blind aims to empower users to make informed decisions and inspire positive changes in their workplaces.
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Dano (다노) is a Korea-based company that develops diet apps for the health and fitness sector. Dano’s Diet App is a journal-based app that enables users to stay focused and monitor their daily progress. The app offers many useful tools to help users stay committed to their diet programs. Dano also released Diet Cover, a lock-screen photo app that enables users to have a photo of their role model, in order to remind themselves about their diet during the course of the day. This app enables users to eat healthily and be mindful of their diet at any given moment. Dano was established in July 2013.
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for serious eye diseases. Founded in 2011 and based in Alpharetta, Georgia, the company utilizes a proprietary ocular microinjection platform to deliver therapies directly to specific compartments of the eye, including the retina and choroid. Its lead product, XIPERE, is a suprachoroidal injectable suspension of triamcinolone acetonide, targeting macular edema associated with conditions such as uveitis and diabetic macular edema. Additionally, Clearside is advancing CLS-AX, an axitinib formulation for suprachoroidal injection. The company's novel SCS Microinjector allows for a non-surgical, repeatable procedure aimed at preserving and restoring vision in patients with sight-threatening eye diseases.
12cm operates echoss, a cloud O2O service platform that provides offline to mobile connection services. The company also offers echoss stamp products. 12cm’s platform also includes a service mobile plugin, commerce service, and coupon service components. In addition, its echoss platform is applied and extended to O2O service, including membership, promotion, mobile certification, commerce, and utility. It is based in Bundangdong, Kyonggi-do.
Remember is the number one business card management application in Korea that secretary inputs directly when you take a business card.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.
Amicogen Inc is an industrial biotechnology company operating in Korea. It is engaged in the development, production, and distribution of enzymes, bio-new materials, and healthcare food. The company's product portfolio includes special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP), and protein A chromatography resins.
Shanghai Fangtek Electronics Co., Ltd. is an integrated circuit design company based in Shanghai, China, with an additional office in Shenzhen. Founded in 2003, Fangtek specializes in the design, development, and marketing of analog and mixed-signal power management integrated circuits. Its product offerings include audio power amplifiers, LED drivers, SIM card controllers, analog switches, reset integrated circuits, charger protection products, and voltage regulators. These products cater to various applications in the communication, computing, and consumer electronics sectors, including mobile phones, GPS devices, and audio equipment. Fangtek is committed to delivering innovative, high-performance, and cost-effective solutions, leveraging its expertise in power device technology and mixed-signal design to serve the needs of industries focused on audio, lighting, and voltage regulation.